Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.

@article{Perner2013LossOS,
  title={Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.},
  author={Sven Perner and Niels J Rupp and Martin Ulrich Braun and Mark A. Rubin and Holger Moch and Manfred Dietel and Nicolas Wernert and Klaus Jung and Carsten Stephan and Glen Kristiansen},
  journal={International journal of cancer},
  year={2013},
  volume={132 4},
  pages={807-12}
}
The majority of prostate cancer harbors recurrent gene fusions involving ETS transcription factors, most commonly ERG. The second most common 5' fusion partner after TMPRSS2 is SLC45A3. The aim of our study was to quantify the protein expression of ERG, TMPRSS2 and SLC45A3 in prostate cancer to assess for diagnostic or prognostic utility. Six hundred and forty consecutive prostate cancer cases in tissue microarray format were immunohistochemically analyzed for ERG, TMPRSS2 and SLC45A3 protein… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

1278–82; discussion 83–4

  • Stibane I Mansour R et al. Complications urinary continenc Lein M, Campus Mitte. Eur Urol 2006 oncologic outcome of 1000 lap Berlin, 50
  • C an ce r C el l B io lo gy Perner et…
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…